Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Akebia Therapeutics (AKBA) Long-Term Investments (2018)

Akebia Therapeutics has reported Long-Term Investments over the past 2 years, most recently at $245000.0 for Q4 2018.

Quarterly Long-Term Investments changed N/A to $245000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $245000.0 through Dec 2018, changed N/A year-over-year, with the annual reading at $245000.0 for FY2018, N/A changed from the prior year.
Long-Term Investments was $245000.0 for Q4 2018 at Akebia Therapeutics, down from $49.6 million in the prior quarter.
Over five years, Long-Term Investments peaked at $49.6 million in Q4 2015 and troughed at $245000.0 in Q4 2018.